CNBC's Angelica Peebles reports on news regarding CVS.
With the first half of 2025 wrapped up, now feels like as good a time as any to check in with the top-performing dividend plays and see how the stage is set for the rest of the year.
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
The S&P 500 is one of the most widely known benchmarks. It contains the 500 most valuable publicly traded U.S.
CVS Health (CVS) closed the most recent trading day at $67.58, moving +1.15% from the previous trading session.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.
CVS surges 53.7% YTD as regulatory relief, strong execution and Medicare Advantage momentum fuel investor confidence.
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.
Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL.